The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …

Hypertension affects two-thirds of people aged> 60 years and significantly increases the risk
of both vascular cognitive impairment and Alzheimer's disease. Hypertension compromises …

Importance The racial and ethnic diversity of the US, including among patients receiving
their care at the Veterans Health Administration (VHA), is increasing. Dementia is a …

This article describes the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality and morbidity, costs of care, and the overall impact on …

Importance Previous estimates suggested that 1 in 3 cases of Alzheimer disease and related
dementia (ADRDs) in the US are associated with modifiable risk factors, the most prominent …

Background Information on the use of aspirin to increase healthy independent life span in
older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend …

Importance Racial and ethnic groups with higher rates of clinical Alzheimer disease (AD) are
underrepresented in studies of AD biomarkers, including amyloid positron emission …

This report describes the public health impact of Alzheimer's disease, including incidence
and prevalence, mortality rates, costs of care, and the overall impact on caregivers and …

Introduction Although dementia prevalence differs by race, it remains unclear whether
cognition and neuropsychiatric symptom severity differ between Black and White individuals …

Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging
population and society as a whole. With the numbers of people with ADRDs predicted to rise …